In last trading session, Third Harmonic Bio Inc (NASDAQ:THRD) saw 0.51 million shares changing hands with its beta currently measuring 2.72. Company’s recent per share price level of $3.47 trading at -$0.11 or -3.07% at ring of the bell on the day assigns it a market valuation of $156.35M. That closing price of THRD’s stock is at a discount of -388.18% from its 52-week high price of $16.94 and is indicating a premium of 8.36% from its 52-week low price of $3.18.
For Third Harmonic Bio Inc (THRD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.33 in the current quarter.
Third Harmonic Bio Inc (NASDAQ:THRD) trade information
Upright in the red during last session for losing -3.07%, in the last five days THRD remained trading in the green while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $3.47 price level, adding 6.22% to its value on the day. Third Harmonic Bio Inc’s shares saw a change of -66.28% in year-to-date performance and have moved 1.17% in past 5-day. Third Harmonic Bio Inc (NASDAQ:THRD) showed a performance of -40.58% in past 30-days.
Wall Street analysts have assigned a consensus price target of 19 to the stock, which implies a rise of 81.74% to its current value. Analysts have been projecting 3.6 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would drop -3.75% in reaching the projected high whereas dropping to the targeted low would mean a loss of -3.75% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around -47.12% while estimates for its earnings growth in next 5 years are of -6.04%.
Third Harmonic Bio Inc (NASDAQ:THRD)’s Major holders
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the top institutional holder at THRD for having 10.91 million shares of worth $141.8 million. And as of 2024-06-30, it was holding 26.8961 of the company’s outstanding shares.
The second largest institutional holder is ORBIMED ADVISORS LLC, which was holding about 5.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 14.2498 of outstanding shares, having a total worth of $75.13 million.
On the other hand, Price (T.Rowe) Small-Cap Value Fund and Fidelity Select Portfolios – Health Care are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 846.79 shares of worth $2.94 million or 1.88% of the total outstanding shares. The later fund manager was in possession of 680.0 shares on Dec 31, 2024 , making its stake of worth around $2.36 million in the company or a holder of 1.51% of company’s stock.
